Relay Therapeutics Inc
RLAY
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.46B
Close$
$-1.47
107.4% downside
Current Fair Value
107.4% downsideOvervalued by 107.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.46 Billion |
|---|---|
| Enterprise Value | $3.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.61 |
| Beta | 1.68 |
| Outstanding Shares | 202,849,466 |
Return
| Return on Equity | -32.14% |
|---|---|
| Return on Assets | -29.57% |
| Return on Invested Capital | -32.52% |
Valuation & Multiples
| P/E Ratio | -12.59 |
|---|---|
| PEG | -66.47 |
| Price to Sales | - |
| Price to Book Ratio | 4.94 |
| Enterprise Value to Revenue | 325.59 |
| Enterprise Value to EBIT | -11.3 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$960,000
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$1.90 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 6.77% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.22%▼ 99.61% |
|---|---|
| Total Invested | $75.12M▼ 95.88% |
| Investors Holding | 38▼ 208.00% |
ESG Score
No data
About Relay Therapeutics Inc
2,020 employeesRelay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.